Tonix Pharmaceuticals (NASDAQ: TNXP) director receives 22,700 stock options grant

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. director Adeoye Y Olukotun reported receiving a stock option grant covering 22,700 shares of common stock. The option has an exercise price of $13.28 per share and expires on May 12, 2036. It was granted under the company’s 2026 Stock Incentive Plan and vests on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders. Following this grant, Olukotun holds stock options for 22,700 underlying shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider OLUKOTUN ADEOYE Y

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	22,700	$0.00	--

Holdings After Transaction: Stock Option — 22,700 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 22,700 shares Exercise price: $13.28 per share Expiration date: May 12, 2036 +1 more

4 metrics

Option grant size 22,700 shares Underlying common stock for new stock option award

Exercise price $13.28 per share Stock option strike price

Expiration date May 12, 2036 Stock option expiration

Post-grant option holdings 22,700 shares Total options held following this transaction

Key Terms

Stock Option, 2026 Stock Incentive Plan, Annual Meeting of Stockholders, Grant, award, or other acquisition

4 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2026 Stock Incentive Plan financial

"The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan"

Annual Meeting of Stockholders financial

"vests on the earlier of the one year anniversary ... and the Issuer's 2027 Annual Meeting of Stockholders"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OLUKOTUN ADEOYE Y

(Last) (First) (Middle)

C/O TONIX PHARMACEUTICALS HOLDING CORP

200 CONNELL DRIVE, SUITE 3100

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tonix Pharmaceuticals Holding Corp. [ TNXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$13.28	05/12/2026		A		22,700		05/12/2027(1)	05/12/2036	Common Stock	22,700	$0.00(1)	22,700	D

Explanation of Responses:

1. The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders.

	/s/ Jessica Morris, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Tonix Pharmaceuticals (TNXP) director Adeoye Y Olukotun acquire in this Form 4?

Adeoye Y Olukotun received a grant of stock options for 22,700 shares of Tonix Pharmaceuticals common stock. These options were issued as compensation under the 2026 Stock Incentive Plan and represent the right to buy shares at a fixed exercise price in the future.

What is the exercise price of the TNXP stock options granted to Adeoye Y Olukotun?

The stock options granted to Adeoye Y Olukotun have an exercise price of $13.28 per share. This means he can buy Tonix Pharmaceuticals common stock at $13.28 per share once the options vest and before they expire, regardless of future market price.

How many Tonix Pharmaceuticals (TNXP) shares are covered by the new option grant?

The new stock option grant covers 22,700 underlying shares of Tonix Pharmaceuticals common stock. These options were reported as a derivative security and, after the grant, Olukotun’s option holdings total 22,700 shares directly tied to this award.

When do the TNXP stock options granted to Adeoye Y Olukotun vest?

The options vest on the earlier of the one-year anniversary of the grant date and Tonix Pharmaceuticals’ 2027 Annual Meeting of Stockholders. This schedule links vesting either to time served or the timing of the shareholder meeting, whichever occurs first.

When do Adeoye Y Olukotun’s Tonix Pharmaceuticals stock options expire?

The granted stock options expire on May 12, 2036. After that expiration date, Adeoye Y Olukotun can no longer exercise the options to purchase Tonix Pharmaceuticals common stock at the fixed $13.28 exercise price specified in the award.

Under what plan were the TNXP stock options for Adeoye Y Olukotun granted?

The options were granted pursuant to Tonix Pharmaceuticals’ 2026 Stock Incentive Plan. This plan is used by the company to provide equity-based compensation, such as stock options, to directors and other eligible participants according to its terms.